comparemela.com

மனு சக்ரவர்த்தி News Today : Breaking News, Live Updates & Top Stories | Vimarsana

MAHE conference from today - The Hindu

Axcella Announces Alison D Schecter, M D , as President of R&D

Experienced biopharma leader to oversee research, candidate development, clinical and regulatory functions CAMBRIDGE, Mass. (BUSINESS WIRE) Axcella (Nasdaq:AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases and improve health using endogenous metabolic modulator (EMM) compositions, today announced the appointment of Alison D. Schecter, M.D., as the company’s President of Research and Development. In this role, Dr. Schecter will oversee all of the company’s research, product candidate design, clinical and regulatory efforts. Additionally, Manu Chakravarthy, M.D., Ph.D., has decided to step down as the company’s Chief Medical Officer to pursue another opportunity.

Making a Case for Going Beyond the Liver to Include Muscles for NAFLD: A Systematic Review Published

Share this article Share this article LINKÖPING, Sweden, Jan. 12, 2021 /PRNewswire/ A perspective review article titled Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis was recently published in Frontiers in Endocrinology as part of a special issue of Non-Alcoholic Steatohepatitis (NASH) Metabolic Contributors and Therapeutic Targets. Authored by scientific experts from Axcella Health, AMRA Medical, Linköping University, and Virginia Commonwealth University (VCU), this paper describes the link between muscle composition and chronic liver diseases, including non-alcoholic fatty liver disease (NAFLD). It discusses in depth the scientific basis of underlying factors outside of the liver to treat NAFLD – affecting nearly one-quarter of the world s adult population.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.